Clinical Trial Update: DApagliflozin Cardiovascular Effects on Patients at End-stage REnal Disease [Phase 4]

View source ↗

Summary

Clinical trial update on dapagliflozin and cardiovascular effects in patients with end-stage kidney disease (Phase 4).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• End-stage Kidney Disease

Drugs mentioned

• Dapagliflozin (dapagliflozin)

Snippet

Sponsor: University of Campinas, Brazil | Conditions: End-stage Kidney Disease | Phase 4 | Status: UNKNOWN